- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02117830
A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects
This is a Phase I, single-site, randomized, double-blinded, double-dummy, placebo- and positive-controlled, 4-period crossover study to evaluate the effect of two dose levels of Androxal on cardiac repolarization. Baseline ECGs will be obtained prior to dosing in each Period and ECGs will be obtained during expected peak plasma concentrations of Androxal and the positive control.
In each Treatment Period subjects will be admitted to a Clinical Research Unit where study drug will be administered as three (3) daily single doses. Treatment Periods will be separated by a washout of at least 7 days between Periods.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Generally healthy males as determined by history and physical examination
- Between the ages of 18 and 60, inclusive
- Clinical laboratory test results within the normal reference ranges for the investigative site or results with acceptable deviations that are judged by the principal investigator to be not clinically significant
Vital signs (after 5 minutes resting in a supine position)
- Systolic blood pressure (SBP) 90-140 mmHg, and
- Diastolic blood pressure (DBP) 50-90 mmHg, and
- Pulse 45-100 bpm Note: subjects with vital signs outside the above ranges may be eligible for the study if the Investigator feels that the results are not clinically significant and will not impact study conduct.
- Body mass index (BMI) ≥25 to ≤42 kg/m2 at Screening
- Are reliable and willing to be available for the duration of the study, abiding by the policies and procedures of the clinical trials unit
- Have given written informed consent
- Subject must be able to speak, read and understand English or Spanish and be willing and able to provide written informed consent in English or Spanish on an Institutional Review Board (IRB)-approved form prior to the initiation of any study procedures. Subject must have signed and dated a written informed consent form (ICF) before undergoing any study related activities, including discontinuation of any prohibited medications.
Exclusion Criteria:
- Repros employee or investigative site personnel and their immediate families
- Participation in a clinical trial within the past 30 days or receipt of any investigational agent or study treatment within 30 days or 5 half-lives, whichever is longer, prior to Screening
- Known hypersensitivity to Clomid
- Known allergy to moxifloxacin
Abnormal electrocardiogram that, after the option of repeating any such findings, in the opinion of the Investigator and/or Sponsor may interfere with any aspect of study conduct or interpretation of results including:
- an abnormality of cardiac rhythm other than sinus arrhythmia
- QTcF > 450 msec
- QTcF < 300 msec
- PR interval >200 msec
- QRS > 110 msec
- abnormal T wave morphology that will impair the ability to measure the QT interval reliably
- History of congenital long QT syndrome or known history of QTc interval prolongation or family history of congenital long QT syndrome
- Evidence of significant cardiac disease, for example, arrhythmia or unexplained syncope within the last year
- History of myocardial infarction, unstable angina, symptomatic heart failure, ventricular dysrhythmia,
- History of thrombophlebitis, thromboembolic disorder or cerebrovascular accident
- Evidence of significant respiratory or hepatic disease
- Use of cigarettes or any tobacco product within 2 weeks prior to Screening and while participating in the study
- Use of any medications other than acetaminophen or aspirin (prescription or over-the-counter), herbal tea , energy drinks, supplements, within 5 days of dosing (prior to first dose of study medications), with the exception of those approved by the Investigator and Sponsor
- Use of drugs of abuse and/or positive findings on drug screen
- Known active infection with HIV or hepatitis B or C.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: Androxal 25 mg
|
|
Experimental: Androxal 250 mg
supratherapeutic dose
|
|
Other: Moxifloxacin 400 mg
positive control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The placebo-subtracted change of the QTc interval from Baseline (ΔΔQTc) defined as: the change of QTc from the subject-specific and period-specific Baseline (ΔQTc), less the time-matched placebo value of change of QTc
Time Frame: 64 days
|
The placebo-subtracted change of the QTc interval from Baseline (ΔΔQTc) defined as: the change of QTc from the subject-specific and period-specific Baseline (ΔQTc), less the time-matched placebo value of change of QTc
|
64 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Hormone Antagonists
- Estrogen Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Moxifloxacin
- Clomiphene
- Enclomiphene
- Zuclomiphene
Other Study ID Numbers
- ZA-108
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo Capsules
-
AfimmuneTerminatedType 2 Diabetes | HypertriglyceridemiaGeorgia, United States, Germany, Israel, Latvia, Switzerland
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
AbbottQuintiles, Inc.Terminated
-
Guang'anmen Hospital of China Academy of Chinese...Beijing Anzhen HospitalCompleted
-
Chinese Academy of Medical Sciences, Fuwai HospitalNational Natural Science Foundation of ChinaRecruiting
-
Caelus Pharmaceuticals BVCompleted
-
Massachusetts General HospitalCompleted
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Reata, a wholly owned subsidiary of BiogenTerminatedConnective Tissue Disease-Associated Pulmonary Arterial HypertensionUnited States, Spain, Japan, Australia, United Kingdom, Canada, Germany, Belgium, Argentina, Israel, Mexico, Brazil, Czechia, Netherlands, Philippines